[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-356192-105":59,"doc-detail-356192-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","biomarkers-in-gastric-cancer-blood-biomarkers-liquid-biopsy-artificial-intelligence-and-risk-stratified-care","Biomarkers in Gastric Cancer - Blood Biomarkers, Liquid Biopsy, Artificial Intelligence, and Risk-Stratified Care","","Gastric cancer is frequently diagnosed at advanced stages in countries lacking organized screening, where non-invasive biomarkers are proposed to risk-stratify adults or those with precursor mucosal lesions for endoscopy. A literature search across PubMed/MEDLINE, Scopus, and Google Scholar (Jan 2006–May 2026) identified 25 diagnostic accuracy and health-economic studies, synthesized narratively under PRISMA-DTA and Ferrari guidance. Results show promising performance across inflammation indices, serological mucosal markers, liquid biopsy platforms, and endoscopic AI, with limitations in early-stage disease; liquid biopsy can reach AUC 0.968.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/biomarkers-in-gastric-cancer-blood-biomarkers-liquid-biopsy-artificial-intelligence-and-risk-stratified-care/356192/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/biomarkers-in-gastric-cancer-blood-biomarkers-liquid-biopsy-artificial-intelligence-and-risk-stratified-care/356192.png","ImageObject",300,407,{"name":92,"@type":93},"pixelkiddo","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-04","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",16,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"Why are non-invasive biomarkers considered for gastric cancer?","Question",{"text":113,"@type":114},"They can help identify high-risk people who may benefit from endoscopy in settings where universal screening is not feasible and gastric cancer is often detected late.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"What marker types were evaluated in the review?",{"text":118,"@type":114},"The review assesses inflammation scores from routine blood counts, blood proteins signaling stomach lining damage, tests detecting circulating tumor DNA/RNA, and artificial intelligence applied to endoscopic images.",{"name":120,"@type":111,"acceptedAnswer":121},"How does diagnostic performance vary across cancer stages?",{"text":122,"@type":114},"Accuracy is promising overall, but performance drops for early-stage cancers and precancerous lesions, which limits direct diagnosis using these biomarkers.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},356192,1790487357,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":140,"language":141,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":67,"update_tm":145,"read_time":146,"preview_page_count":19,"preview_urls":147},962090883892,"https://ap-avatar.wpscdn.com/avatar/e00115db34f3e0f11b?x-image-process=image/resize,m_fixed,w_180,h_180&k=1790152879550218658","Review  \nBiomarkers in Gastric Cancer: Blood Biomarkers, Liquid Biopsy, Artificial Intelligence, and Risk-Stratified Care  \nHelen D. Kim 1, Bryant Morocho 2,3, Elliott Lee 3 and Steve Kwon 4, *  \nAcademic Editor: Hidekazu Suzuki  \nReceived: 30 July 2026  \nRevised: 18 August 2026  \nAccepted: 25 August 2026  \nPublished: 28 August 2026  \nCopyright: © 2026 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license.  \n1 Warren Alpert Medical School, Brown University, Providence, RI 02903, USA; [helen_d_kim@brown.edu](helen_d_kim@brown.edu)  \n2 Department of Surgery, Division of Surgical Oncology, Roger Williams Medical Center, Providence, RI 02908, USA; [bryant.morocho@chartercare.org](bryant.morocho@chartercare.org)  \n3 Department of Surgery, Roger Williams Surgery and Cancer Outcomes Research and Equity (RWSCORE) Center, Roger Williams Medical Center, Providence, RI 02908, USA  \n4 Department of Surgery, Division of Surgical Oncology, Yale University School of Medicine, New Haven, CT 06510, USA  \n* Correspondence: [sung.kwon@yale.edu](sung.kwon@yale.edu)  \nSimple Summary  \nDiagnosing gastric cancer early improves five-year survival from 8% to 78% . Endoscopy is accurate but too costly for universal screening in Western countries. This review examines whether simpler diagnostic tests/markers may help identify a high-risk group of people who may benefit from endoscopy. We assessed four groups of markers: inflammation scores from routine blood counts, blood proteins that signal damage to the stomach lining, tests that detect tumor DNA or RNA circulating in the blood, and artificial intelligence applied to endoscopic images. Accuracy across studies was promising, but most data come from retrospective East Asian case–control studies. Performance drops significantly for early-stage cancers and precancerous lesions. We conclude these non-invasive markers are best used to triage high-risk patients for endoscopy rather than replace it, and prospective studies in symptom-free Western populations remain essential.  \nAbstract  \nBackground: Gastric cancer is often diagnosed in advanced stages for patients in countries without organized screening processes. Non-invasive biomarkers have been proposed to risk-stratify and identify those who should undergo endoscopy. Methods: We searched PubMed/MEDLINE, Scopus, and Google Scholar for studies published between January 2006 and May 2026 reporting diagnostic accuracy or health–economic outcomes for gastric cancer detection in asymptomatic adults or patients with precursor mucosal lesions. Twenty-five studies met eligibility criteria and were synthesized narratively, with reporting informed by PRISMA-DTA and Ferrari guidance. Results: Systemic inflammatory indices derived from routine blood counts are inexpensive but non-specific, with individual areas under the receiver operating characteristic curve (AUC) between 0.65 and 0.83 . Serological markers of mucosal atrophy have a clearer biological basis and carry the review’s only large Western validation dataset but preferentially detect corpus-predominant disease. Liquid biopsy platforms report the highest accuracy, up to an AUC of 0.968, though sensitivity falls to 62.4% for precancerous lesions and to 44% for stage I disease on some platforms. Magnifying narrow-band imaging reported the highest accuracy among the endoscopic modalities reviewed, with an AUC of 0.97 . In low-incidence Western settings, one-time serum pepsinogen screening with endoscopy reserved for positive results is cost-effective at USD 4913 per QALY gained. Conclusions: Reported accuracy is encouraging across all four classes of gastric cancer markers but derives mainly from retrospective East Asian case–control cohorts and declines at the earliest stages of disease. The evidence supports  \nusing these markers to triage toward endoscopy rather than to diagno","cbCaimbLpxUDy7MV","https://ap.wps.com/l/cbCaimbLpxUDy7MV","pdf",2042113,27,"English","# Simple Summary\n# Abstract\n# Keywords\n# 1. Introduction\n# Esophagogastroduodenoscopy (EGD) as a Gold Standard\n## Incidence and Regional Differences\n## Age-Standardized Incidence Trends","[{\"question\":\"Why are non-invasive biomarkers considered for gastric cancer?\",\"answer\":\"They can help identify high-risk people who may benefit from endoscopy in settings where universal screening is not feasible and gastric cancer is often detected late.\"},{\"question\":\"What marker types were evaluated in the review?\",\"answer\":\"The review assesses inflammation scores from routine blood counts, blood proteins signaling stomach lining damage, tests detecting circulating tumor DNA/RNA, and artificial intelligence applied to endoscopic images.\"},{\"question\":\"How does diagnostic performance vary across cancer stages?\",\"answer\":\"Accuracy is promising overall, but performance drops for early-stage cancers and precancerous lesions, which limits direct diagnosis using these biomarkers.\"}]","Biomarkers in Gastric Cancer - Blood Biomarkers, Liquid Biopsy, Artificial Intelligence, and Risk-Stratified Care | PDF",1790123969,68,[148,152,156,160],{"page_no":8,"url":149,"width":150,"height":151},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/2a7ce5068e7f8828be6179d0d1705d3c.webp",983,1390,{"page_no":14,"url":153,"width":154,"height":155},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/5786f6f4729ac47c95564fd060752489.webp",982,1388,{"page_no":81,"url":157,"width":158,"height":159},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/247aa9ecb2efbefe2599b018c40816da.webp",981,1387,{"page_no":19,"url":161,"width":162,"height":163},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/704cf0cfd3b968d3b22515904e716cc9.webp",980,1385]